Literature DB >> 3123452

Factors affecting the in-vitro activity of roxithromycin.

J M Andrews1, J P Ashby, R Wise.   

Abstract

The effect of human serum and CO2 on the activity of roxithromycin and erythromycin was assessed. Protein binding of roxithromycin in serum from various animal sources, acid alpha 1-glycoprotein and human albumin V was determined. There was a four- to eight-fold increase in MIC and MBC of roxithromycin in the presence of 70 and 100% human serum (minimum effect seen with erythromycin) and for both compounds there was a four- to eight-fold increase in MIC for fastidious organisms in the presence of CO2. Roxithromycin appears to be selectively bound to acid alpha 1-glycoprotein, binding decreases with an increase in roxithromycin concentration (saturable at 10 mg/l) and protein binding is variable depending on animal source (86% human, 10% guinea pig) and this must be considered when data on activity from animal studies are evaluated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3123452     DOI: 10.1093/jac/20.suppl_b.31

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

2.  Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.

Authors:  Michael J Dolton; David Z D'Argenio
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

3.  Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment.

Authors:  Yu-Mei Tan; Hugh A Barton; Alan Boobis; Rachel Brunner; Harvey Clewell; Rhian Cope; Jeffrey Dawson; Jeanne Domoradzki; Peter Egeghy; Pankaj Gulati; Brandall Ingle; Nicole Kleinstreuer; Kelly Lowe; Anna Lowit; Elizabeth Mendez; David Miller; Jeffrey Minucci; James Nguyen; Alicia Paini; Monique Perron; Katherine Phillips; Hua Qian; Tharacad Ramanarayanan; Fiona Sewell; Philip Villanueva; John Wambaugh; Michelle Embry
Journal:  Regul Toxicol Pharmacol       Date:  2021-10-28       Impact factor: 3.598

Review 4.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

5.  Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.

Authors:  M Masud Parvez; Jin Ah Jung; Ho Jung Shin; Dong Hyun Kim; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

6.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 7.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.